Re: Re: RESEARCH - Anti-CCP antibodies measured at disease onset help identify seronegative RA and predict outcome

[Guest guest]

Doreen,

I'm not sure what you are asking.

Which tests did you have and what were the results?

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org

[ ] Re: RESEARCH - Anti-CCP antibodies measured at disease

onset help identify seronegative RA and predict outcome

Hi I have had the new testing to see if the anti bodies would show if

I have or ever have RA now or in the future what I am confused about

is this.

My RA factor for both were high and the rhuemy after this test said

that it is not RA nor will it ever be I think the genetic or

anitbodies that new testing? How can that be when each time the RA

in the blood work show yes?

Doreen

--- In , " " <Matsumura_Clan@...>

wrote:

>

> Rheumatology Advance Access originally published online on November

15, 2005

> Rheumatology 2006 45(4):478-480; doi:10.1093/rheumatology/kei203

>

> © The Author 2005. Published by Oxford University Press on behalf

of the

> British Society for Rheumatology. All rights reserved. For

Permissions,

> please email: journals.permissions@...

>

>

>

> Anti-CCP antibodies measured at disease onset help identify

seronegative

> rheumatoid arthritis and predict radiological and functional outcome

>

>

> M. A. Quinn, A. K. S. Gough, M. J. Green, J. Devlin, E. M. A.

Hensor, A.

> Greenstein, A. Fraser and P. Emery

> Academic Unit of Musculoskeletal Disease, Department of

Rheumatology, Chapel

> Allerton Hospital, Chapeltown Road, Leeds LS74SA, UK.

>

>

> Correspondence to: M. A. Quinn. E-mail: Mark.Quinn@...

>

> Objective. Anti-cyclic citrullinated peptide (anti-CCP) antibodies

have been

> identified as highly specific for rheumatoid arthritis (RA).

Studies suggest

> an association with radiographic outcome. The aims of this study

were to

> assess the diagnostic and prognostic utility of the second-

generation

> anti-CCP2 test in a large cohort of early RA patients compared with

> connective tissue disease (CTD) controls.

>

> Methods. One hundred and eighty-two patients with RA and 121

patients with

> CTD were recruited. All RA patients had less than 24 months of

symptoms and

> had CRP, rheumatoid factor (RF), HLA typing (SE) and anti-CCP2

antibodies

> measured at baseline. Function was assessed using the Health

Assessment

> Questionnaire (HAQ) and X-rays performed at 0, 12 and 24 months.

>

> Results. The anti-CCP2 antibody test demonstrated a specificity of

91% and

> sensitivity of 81% for RA when compared with controls. In RF-

negative

> patients, specificity was 92% and sensitivity 60%. Baseline

demographics of

> the RA cohort showed mean age 57 yr, mean symptom duration 7

months, 63%

> RF-positive patients, 72% SE-positive, 81% CCP-positive and 21%

erosive. The

> only predictor of change in Larsen score from 0 to 24 months in the

cohort

> was the presence of the shared epitope (P<0.05) and in the RF-

negative

> subgroup it was CCP2 antibody titre >100 (P<0.05). Baseline HAQ was

the only

> significant predictor of HAQ at 24 months, but in the RF-negative

subgroup

> CCP2 antibody titre >100 predicted a poor functional response at 24

months

> (P<0.05).

>

>

> Conclusions. This study confirms the diagnostic utility of anti-CCP2

> antibodies in early RA, particularly in seronegative patients, in

whom

> anti-CCP2 positivity also conferred prognostic utility for

radiographic and

> functional outcomes.

>

>

> http://rheumatology.oxfordjournals.org/cgi/content/abstract/45/4/478

>